NL9301562A - Preparaat voor substitutietherapie. - Google Patents

Preparaat voor substitutietherapie. Download PDF

Info

Publication number
NL9301562A
NL9301562A NL9301562A NL9301562A NL9301562A NL 9301562 A NL9301562 A NL 9301562A NL 9301562 A NL9301562 A NL 9301562A NL 9301562 A NL9301562 A NL 9301562A NL 9301562 A NL9301562 A NL 9301562A
Authority
NL
Netherlands
Prior art keywords
day
estrogen
dose
days
progestin
Prior art date
Application number
NL9301562A
Other languages
English (en)
Dutch (nl)
Original Assignee
Saturnus Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saturnus Ag filed Critical Saturnus Ag
Priority to NL9301562A priority Critical patent/NL9301562A/nl
Priority to CA002171460A priority patent/CA2171460C/en
Priority to CN94193713A priority patent/CN1076969C/zh
Priority to JP7508461A priority patent/JPH09502194A/ja
Priority to EP94927583A priority patent/EP0717626B1/en
Priority to US08/605,118 priority patent/US5827843A/en
Priority to KR1019960701195A priority patent/KR960704553A/ko
Priority to AU76952/94A priority patent/AU708881B2/en
Priority to HU9600592A priority patent/HU224818B1/hu
Priority to PCT/EP1994/002997 priority patent/WO1995007081A1/en
Priority to AT94927583T priority patent/ATE241362T1/de
Priority to DE69432752T priority patent/DE69432752T2/de
Publication of NL9301562A publication Critical patent/NL9301562A/nl
Priority to FI961098A priority patent/FI961098A/fi
Priority to AU18488/99A priority patent/AU1848899A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
NL9301562A 1993-09-09 1993-09-09 Preparaat voor substitutietherapie. NL9301562A (nl)

Priority Applications (14)

Application Number Priority Date Filing Date Title
NL9301562A NL9301562A (nl) 1993-09-09 1993-09-09 Preparaat voor substitutietherapie.
AU76952/94A AU708881B2 (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one estrogen
HU9600592A HU224818B1 (en) 1993-09-09 1994-09-08 The use of progestogen and estrogen for manufacturing a pharmaceutical composition for substitution therapy and oral contraception
JP7508461A JPH09502194A (ja) 1993-09-09 1994-09-08 少なくとも１種のプロゲストーゲンおよび少なくとも１種のエストロゲンを含む、代替療法用製剤
EP94927583A EP0717626B1 (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
US08/605,118 US5827843A (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one estrogen
KR1019960701195A KR960704553A (ko) 1993-09-09 1994-09-08 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen)
CA002171460A CA2171460C (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
CN94193713A CN1076969C (zh) 1993-09-09 1994-09-08 含有至少一种孕激素和至少一种雌激素的替代治疗用制剂
PCT/EP1994/002997 WO1995007081A1 (en) 1993-09-09 1994-09-08 Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
AT94927583T ATE241362T1 (de) 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
DE69432752T DE69432752T2 (de) 1993-09-09 1994-09-08 Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
FI961098A FI961098A (fi) 1993-09-09 1996-03-08 Menetelmä progestogeniä ja estrogeniä sisältävän korvikkeen valmistamiseksi
AU18488/99A AU1848899A (en) 1993-09-09 1999-02-26 Preparation for substitution therapy, containing at least one progestogen and at least one estrogen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9301562A NL9301562A (nl) 1993-09-09 1993-09-09 Preparaat voor substitutietherapie.
NL9301562 1993-09-09

Publications (1)

Publication Number Publication Date
NL9301562A true NL9301562A (nl) 1995-04-03

Family

ID=19862861

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9301562A NL9301562A (nl) 1993-09-09 1993-09-09 Preparaat voor substitutietherapie.

Country Status (12)

Country Link
US (1) US5827843A (fi)
EP (1) EP0717626B1 (fi)
JP (1) JPH09502194A (fi)
KR (1) KR960704553A (fi)
CN (1) CN1076969C (fi)
AT (1) ATE241362T1 (fi)
AU (1) AU708881B2 (fi)
DE (1) DE69432752T2 (fi)
FI (1) FI961098A (fi)
HU (1) HU224818B1 (fi)
NL (1) NL9301562A (fi)
WO (1) WO1995007081A1 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
WO1998004268A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
WO1998004246A2 (en) * 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
WO2001052857A1 (en) * 2000-01-18 2001-07-26 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
HRP20020666B1 (en) * 2000-01-18 2011-07-31 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
CN1555266A (zh) * 2001-03-16 2004-12-15 激素替代疗法
EP1857110A3 (en) * 2001-03-16 2008-08-06 Wyeth Hormone replacement therapy
AU2002309919B2 (en) * 2001-05-16 2008-04-10 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
ATE350041T1 (de) * 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
DE60223795T2 (de) * 2001-05-23 2008-11-27 Pantarhei Bioscience B.V. Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption
EP1390041B1 (en) * 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003006027A1 (en) * 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE60216630T2 (de) * 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
BRPI0214716B8 (pt) * 2001-12-05 2021-05-25 Teva Womens Health Inc kit, preparos, e uso de estrogênio e progestina na fabricação de um medicamento para uso na prevenção de gravidez
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
AU2003274941A1 (en) * 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
SI1511496T1 (sl) * 2002-06-11 2007-04-30 Pantarhei Bioscience Bv Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
CA2492287C (en) * 2002-07-12 2011-12-13 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
AU2003274823A1 (en) 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CN101001631B (zh) * 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
CA2674325A1 (en) * 2007-01-08 2008-07-17 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275716A1 (en) * 1986-12-29 1988-07-27 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, and fertility control kit comprising said dosage unit.
EP0279977A2 (en) * 1987-02-26 1988-08-31 Alza Corporation Transdermal administration of progesterone, estradiol esters and mixtures thereof
EP0559240A2 (en) * 1987-09-24 1993-09-08 Jencap Research Limited Hormone composition containing estrogen and mogestin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275716A1 (en) * 1986-12-29 1988-07-27 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, and fertility control kit comprising said dosage unit.
EP0279977A2 (en) * 1987-02-26 1988-08-31 Alza Corporation Transdermal administration of progesterone, estradiol esters and mixtures thereof
EP0559240A2 (en) * 1987-09-24 1993-09-08 Jencap Research Limited Hormone composition containing estrogen and mogestin

Also Published As

Publication number Publication date
AU7695294A (en) 1995-03-27
JPH09502194A (ja) 1997-03-04
HU9600592D0 (en) 1996-05-28
DE69432752T2 (de) 2004-04-08
HUT74452A (en) 1996-12-30
EP0717626A1 (en) 1996-06-26
CN1133011A (zh) 1996-10-09
KR960704553A (ko) 1996-10-09
DE69432752D1 (de) 2003-07-03
FI961098A (fi) 1996-04-03
FI961098A0 (fi) 1996-03-08
ATE241362T1 (de) 2003-06-15
EP0717626B1 (en) 2003-05-28
CN1076969C (zh) 2002-01-02
HU224818B1 (en) 2006-02-28
AU708881B2 (en) 1999-08-12
US5827843A (en) 1998-10-27
WO1995007081A1 (en) 1995-03-16

Similar Documents

Publication Publication Date Title
NL9301562A (nl) Preparaat voor substitutietherapie.
US5898032A (en) Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
EP0402950B1 (en) Treatment of postmenopausal disorders
KR960001371B1 (ko) 폐경기 전의 여성용 혼합 제형 및 이를 포함하는 팩
Sherif Benefits and risks of oral contraceptives
CN1137691C (zh) 基于天然雌激素的多相避孕制剂
Regidor et al. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone
DK174071B1 (da) Kontraceptivt præparat i form af en pakning omfattende enhedsdoser
SK83196A3 (en) Contaceptive agent
JPH09502733A (ja) ホルモン避妊及び／又はざ瘡治療のための手段及び方法
Grow Metabolism of endogenous and exogenous reproductive hormones
SK8872001A3 (en) Triphasic oral contraceptive
Mora et al. Clinical evaluation of an oral progestin contraceptive, R-2323, 5mg, administered at weekly intervals
CA2392841A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
Bergstein Clinical efficacy, acceptability and metabolic effects of new low dose combined oral contraceptives
Tuimala et al. A clinical comparison in Finland of two oral contraceptives containing 0.150 mg desogestrel in combination with 0.020 mg or 0.030 mg ethinylestradiol
Zador Fertility regulation using “triphasic” administration of ethinyl estradiol and levonorgestrel in comparison with the 30 plus 150 μg fixed dose regime
Andolsek Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent
CA2171460C (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
Bertone et al. Low dose oestrogens and endometrial cancer
Tadmor et al. The effect of desogestrel for hormone replacement therapy on the blood lipid profiles of postmenopausal women
DK174181B1 (da) Farmaceutisk præparat til hormonbehandling
Chez The new progestins
Giwa-Osagie Metabolic effects of once-a-month combined injectable contraceptives
Otolorin Clinical experience with a triphasic oral contraceptive containing ethinyloestradiol and levonorgestrel

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed